Connection
Jean Mulcahy Levy to Molecular Targeted Therapy
This is a "connection" page, showing publications Jean Mulcahy Levy has written about Molecular Targeted Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.361 |
|
|
|
-
Kotch C, Perreault S, Power P, Adams DJ, Aldape K, Avery RA, Bandopadhayay P, Capper D, de Blank P, Entz-Werle N, Fangusaro J, Hansford JR, Hawkins C, Jacques TS, Jones DTW, Kann BH, Kranendonk MEG, Levine A, Ligon KL, Martinez-Barbera JP, Meijer L, Milde T, Mueller S, Mulcahy Levy JM, Nakano Y, Packer RJ, Pfister S, Raabe E, Robison NJ, Tabori U, Yeo KK, Vinitsky A, Zhu Y, Fisher MJ, Hargrave D, Kilburn LB. Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma. Neuro Oncol. 2026 09 01; 28(9):2110-2122.
Score: 0.192
-
Mulcahy Levy JM, Thorburn A. Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ. 2020 03; 27(3):843-857.
Score: 0.121
-
Schreck KC, de la Fuente MI, Lim Fat MJ, Maas SLN, Mulcahy Levy JM, Lombardi G, Perrault S, Petritsch CK, Aldape K, Chang SM, Duerinck J, Holdhoff M, Kazda T, Le Rhun E, Minniti G, Mishra MV, Mueller S, Padovan M, Preusser M, Smits M, Weller M, Wen PY, van den Bent M, Geurts M. BRAF-altered glioma in adults and children: A Society for Neuro-Oncology and European Association of Neuro-Oncology consensus review on clinical management and future directions. Neuro Oncol. 2026 Oct 01; 28(10):2313-2335.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|